Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions

Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.